Related Experiment Video
Updated: Jul 4, 2026

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
Published on: January 18, 2021
Abstract:
In a clinical trial in patients with early-stage Parkinson's disease, rotigotine transdermal patches were less effective than oral ropinirole. In another trial, rotigotine was no more effective than pramipexole in patients with advanced Parkinson's disease. Transdermal delivery does not prevent the systemic adverse effects of rotigotine, and there is an additional risk of local reactions. Treatment is also more difficult to titrate. Patients with Parkinson's disease, whatever the stage, would be well advised to continue using an oral dopamine agonist such as bromocriptine.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
